153 related articles for article (PubMed ID: 38706223)
1. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
4. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
6. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
[TBL] [Abstract][Full Text] [Related]
7. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
[TBL] [Abstract][Full Text] [Related]
11. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment for familial amyloid polyneuropathy.
Magrinelli F; Fabrizi GM; Santoro L; Manganelli F; Zanette G; Cavallaro T; Tamburin S
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012395. PubMed ID: 32311072
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
14. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
[TBL] [Abstract][Full Text] [Related]
15. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.
Masuda T; Ueda M; Suenaga G; Misumi Y; Tasaki M; Izaki A; Yanagisawa Y; Inoue Y; Motokawa H; Matsumoto S; Mizukami M; Arimura A; Deguchi T; Nishio Y; Yamashita T; Inomata Y; Obayashi K; Ando Y
Neurology; 2017 Jun; 88(23):2192-2197. PubMed ID: 28490654
[TBL] [Abstract][Full Text] [Related]
16. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
Sanso MAR; Rodriguez AR; Vicente LM; Sevilla T; Garro CB; Martín JF; Vicente AA; de la Prida MM; Dávila LG; Vázquez LG; Valle FM; Pons CC; Bau AF; Barroso EC; López IL; González-Moreno J
Med Clin (Barc); 2024 May; 162(9):e27-e32. PubMed ID: 38556397
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
Cruz MW
Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
